INTELLIGENCE: AMICUS THERAPUTICS JUMPS 23%, SEVEN POTENTIAL BIOTECH BUYOUT TARGETS $FOLD $BMRN $EXEL $INCY $MDVN $RARE $SGEN $TSRO

This post was just published on ZYX Buy Change Alert. FOLD plans to submit a new drug application to FDA for the oral precision medicine migalastat for Fabry disease.  The stock is jumping on the news. We are not ...
Read more »

INTELLIGENCE: SEVEN POTENTIAL BIOTECH BUYOUT TARGETS IN WAKE OF ARIAD BUYOUT $ARIA $BMRN $EXEL $FOLD $INCY $MDVN $RARE $SGEN $TSRO

This post was just published on ZYX Buy Change Alert. For us to recommend, a stock must pass at least four of the six screens. We prefer a stock to meet all six screens. Our rigorous criteria has ...
Read more »

You are receiving less than 2% of the content from our paid services ...TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES.

Please click here to take advantage of a FREE 30 day trial.

Check out our enviable performance in both bull and bear markets.

INTELLIGENCE: EIGHT POTENTIAL BUYOUT TARGETS IN THE WAKE OF MEDIVATION BUYOUT $ARIA $BMRN $EXEL $FOLD $INCY $RARE $SGEN $TSRO $MDVN $PFE

This post was just published on ZYX Buy Change Alert. For us to recommend, a stock must pass at least four of the six screens. We prefer a stock to meet all six screens. Our rigorous criteria ...
Read more »

TIGHTEN STOPS ON CANCER STOCKS

We have profits on both our long and short cancer trades. Our analysis indicates that it is time to either take profits and exit the positions or make stops extremely tight so that profits ...
Read more »

You are receiving less than 2% of the content from our paid services ...TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES.

Please click here to take advantage of a FREE 30 day trial.

Check out our enviable performance in both bull and bear markets.

CONSIDER LIGHTLY ADDING TO CANCER STOCK SHORTS ON THIS RALLY

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of ...
Read more »

STATUS OF CANCER STOCKS

Per our earlier post, we are short on OSIP from $32.2, SNTA from $3.50and EXEL from $5.35.We are long on PARD from $4.45www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO ...
Read more »

ENCOURAGING DATA AT ASCO

Our review of the data presented at 2009 Annual Meeting of the American Society of Clinical Oncology held in Orlando shows that the following stocks may move in response to the data:SNTA,ZIOP,CLDX,EXEL,BVTI,ABII,OGXI,INFI,OSIP AND PARD.If the ...
Read more »
Follow

Get every new post delivered to your Inbox

Join other followers